These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 18377693)

  • 1. Co-enzyme Q10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA methylation in breast cancer patients undergoing tamoxifen therapy.
    Premkumar VG; Yuvaraj S; Shanthi P; Sachdanandam P
    Br J Nutr; 2008 Dec; 100(6):1179-82. PubMed ID: 18377693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy.
    Premkumar VG; Yuvaraj S; Sathish S; Shanthi P; Sachdanandam P
    Vascul Pharmacol; 2008; 48(4-6):191-201. PubMed ID: 18407793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin.
    Premkumar VG; Yuvaraj S; Vijayasarathy K; Gangadaran SG; Sachdanandam P
    Basic Clin Pharmacol Toxicol; 2007 Jun; 100(6):387-91. PubMed ID: 17516992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ameliorating effect of coenzyme Q10, riboflavin and niacin in tamoxifen-treated postmenopausal breast cancer patients with special reference to lipids and lipoproteins.
    Yuvaraj S; Premkumar VG; Vijayasarathy K; Gangadaran SG; Sachdanandam P
    Clin Biochem; 2007 Jun; 40(9-10):623-8. PubMed ID: 17425952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmented antioxidant status in Tamoxifen treated postmenopausal women with breast cancer on co-administration with Coenzyme Q10, Niacin and Riboflavin.
    Yuvaraj S; Premkumar VG; Vijayasarathy K; Gangadaran SG; Sachdanandam P
    Cancer Chemother Pharmacol; 2008 May; 61(6):933-41. PubMed ID: 17668211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Coenzyme Q(10), Riboflavin and Niacin on Tamoxifen treated postmenopausal breast cancer women with special reference to blood chemistry profiles.
    Yuvaraj S; Premkumar VG; Shanthi P; Vijayasarathy K; Gangadaran SG; Sachdanandam P
    Breast Cancer Res Treat; 2009 Mar; 114(2):377-84. PubMed ID: 18427979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy.
    Premkumar VG; Yuvaraj S; Vijayasarathy K; Gangadaran SG; Sachdanandam P
    Biol Pharm Bull; 2007 Feb; 30(2):367-70. PubMed ID: 17268082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmented efficacy of tamoxifen in rat breast tumorigenesis when gavaged along with riboflavin, niacin, and CoQ10: effects on lipid peroxidation and antioxidants in mitochondria.
    Perumal SS; Shanthi P; Sachdanandam P
    Chem Biol Interact; 2005 Feb; 152(1):49-58. PubMed ID: 15766922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients.
    Fiegl H; Millinger S; Mueller-Holzner E; Marth C; Ensinger C; Berger A; Klocker H; Goebel G; Widschwendter M
    Cancer Res; 2005 Feb; 65(4):1141-5. PubMed ID: 15734995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
    Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
    J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients.
    Cerne JZ; Zong L; Jelinek J; Hilsenbeck SG; Wang T; Oesterreich S; McGuire SE
    Breast Cancer Res Treat; 2012 Aug; 135(1):135-43. PubMed ID: 22706629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.
    Zhang Y; Sieuwerts AM; McGreevy M; Casey G; Cufer T; Paradiso A; Harbeck N; Span PN; Hicks DG; Crowe J; Tubbs RR; Budd GT; Lyons J; Sweep FC; Schmitt M; Schittulli F; Golouh R; Talantov D; Wang Y; Foekens JA
    Breast Cancer Res Treat; 2009 Jul; 116(2):303-9. PubMed ID: 18821012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.
    van Agthoven T; Sieuwerts AM; Meijer-van Gelder ME; Look MP; Smid M; Veldscholte J; Sleijfer S; Foekens JA; Dorssers LC
    J Clin Oncol; 2009 Feb; 27(4):542-9. PubMed ID: 19075277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.
    Rokavec M; Schroth W; Amaral SM; Fritz P; Antoniadou L; Glavac D; Simon W; Schwab M; Eichelbaum M; Brauch H
    Cancer Res; 2008 Dec; 68(23):9799-808. PubMed ID: 19047159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer.
    Osborne CR; Duncan A; Sedlacek S; Paul D; Holmes F; Vukelja S; Kasper M; Wilks S; Schneider A; McGee R; Meyer WG; O'Shaughnessy JA
    Breast Cancer Res Treat; 2009 Aug; 116(3):521-7. PubMed ID: 19139988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response.
    Helleman J; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; Meijer-van Gelder ME; Sieuwerts AM; Klijn JG; Sleijfer S; Foekens JA; Berns EM
    Clin Cancer Res; 2008 Sep; 14(17):5555-64. PubMed ID: 18765548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen treatment in Danish breast cancer patients and 5-year risk of arterial atherosclerotic events: a null association.
    Hernandez RK; Sørensen HT; Jacobsen J; Pedersen L; Lash TL
    Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2509-11. PubMed ID: 18768523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
    Lipton A; Leitzel K; Chaudri-Ross HA; Evans DB; Ali SM; Demers L; Hamer P; Brown-Shimer S; Pierce K; Gaur V; Carney W
    J Clin Oncol; 2008 Jun; 26(16):2653-8. PubMed ID: 18443351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.